Bioequivalence Study of Apixaban Tablets in Healthy Chinese Subjects
Status:
Completed
Trial end date:
2021-04-07
Target enrollment:
Participant gender:
Summary
To evaluate the single-center, open, randomized, single-dose, two-cycle, two-sequence,
cross-over bioequivalence of test preparation apixaban tablet 2.5mg and reference preparation
2.5mg in healthy adult subjects in fasting and fed state